IDBiologics develops human monoclonal antibodies (mAbs) for the prevention and treatment of infectious diseases, utilizing a fully human mAb platform for rapid discovery and optimization of therapeutic candidates. The company has a diverse pipeline with six clinical lead candidates targeting various viral pathogens, supported by robust animal proof-of-concept data.
Funding
Funding not disclosed
Founders
Product
Problem
Infectious diseases pose a significant threat to global health, requiring rapid development of effective preventative and therapeutic measures. Traditional methods for discovering and developing antibody-based treatments can be slow and may not always yield fully human antibodies, potentially limiting their efficacy and increasing the risk of adverse immune responses.
Solution
IDBiologics leverages a fully human monoclonal antibody (mAb) platform to accelerate the discovery and optimization of therapeutic candidates for infectious diseases. This platform enables the rapid identification of broad and potent mAbs with neutralizing activity against a range of viral targets. The company's approach aims to develop effective antibody medicines to combat existing and emerging infectious disease threats.
Target Audience
The primary target audience includes individuals at risk of or infected with infectious diseases, as well as government and healthcare organizations seeking advanced preventative and therapeutic solutions.
Features
- Fully human mAb platform for rapid discovery and optimization
- Broad pipeline of therapeutic antibodies for infectious diseases
- Six clinical lead candidate molecules targeting diverse viral pathogens
- Robust animal proof-of-concept (POC) data supporting clinical candidates
- mAbs with neutralizing activity to a range of viral targets